Largactil (Chlorpromazine Hydrochloride)

Chlorpromazine blocks dopamine D2 receptors in the brain, reducing excess dopaminergic activity that contributes to psychosis. It also antagonizes histamine, muscarinic, and alpha‑adrenergic receptors, which adds sedative, anti‑emetic, and blood‑pressure‑lowering effects.

The appropriate dose of Largactil is determined by the prescribing clinician based on the patient’s condition, severity, age, weight, and response to therapy. Dosage adjustments may be needed for renal or hepatic impairment, and the prescriber will provide specific instructions.

Chlorpromazine is classified as Pregnancy Category B, indicating no proven risk in animal studies but limited human data. It should be used only if the potential benefit justifies any potential risk to the fetus. Breastfeeding mothers should consult their physician, as the drug can pass into milk.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Largactil (chlorpromazine) is a first‑generation, phenothiazine antipsychotic. Compared with newer atypical agents, it has a broader receptor profile, leading to more pronounced sedation, anticholinergic effects, and risk of extrapyramidal symptoms, but it remains effective for acute agitation and refractory nausea.

Largactil should be stored at ambient temperature, preferably below 25 °C, in its original packaging. Keep it away from moisture, direct sunlight, and sources of heat. Do not freeze the product, and ensure the container is tightly closed when not in use.

Largactil is supplied as an injectable solution for intramuscular or intravenous administration. The healthcare professional selects the route based on clinical need, injects the appropriate volume into a muscle or vein, and monitors the patient for therapeutic response and any adverse reactions.

Serious risks include extrapyramidal symptoms such as severe muscle rigidity, neuroleptic malignant syndrome—a rare but life‑threatening reaction with fever and autonomic instability—and cardiac arrhythmias, especially QT prolongation. Prompt medical attention is required if any of these occur.

Largactil is contraindicated in patients with known hypersensitivity to chlorpromazine or any phenothiazine, those with severe central nervous system depression, and individuals with a history of malignant hyperthermia. Caution is also advised for patients with uncontrolled cardiovascular disease, glaucoma, or significant hepatic impairment.